Literature DB >> 26259778

Microvascular invasion patterns affect survival in hepatocellular carcinoma patients after second hepatectomy.

Yi-fu Hou1, Yong-gang Wei2, Jia-yin Yang1, Tian-fu Wen1, Ming-qing Xu1, Lv-nan Yan1, Bo Li1, Ke-fei Chen1.   

Abstract

BACKGROUND: Microvascular invasion (MVI) is an important risk factor for survival of patients with hepatocellular carcinoma (HCC) after hepatectomy. However, its impact on patients with recurrent HCC who receive a second hepatectomy is unknown.
METHODS: We enrolled 167 patients with HCC who underwent a second hepatectomy because of intrahepatic recurrences. We compared the patients' demographic, tumor, and pathologic characteristics with 766 cases of original hepatectomy. We analyzed the possible risk factors for survival after the first and second hepatectomies and the influence of different MVI patterns on patients' survival after the second hepatectomy.
RESULTS: The median overall survival was comparable between the first and second hepatectomy groups, 34 (3-84) mo versus 27 (3-57) mo, P = 0.09. For patients who underwent a first hepatectomy, the presence of macro-VI or MVI, an early recurrence pattern, and a total tumor diameter >5 cm were independent risk factors. For survival after the second hepatectomy, MVI patterns that were positive-positive or negative-positive and a total recurrent tumor diameter >5 cm were significant risk factors for survival.
CONCLUSIONS: A second hepatectomy provides satisfying survival for patients with intrahepatic recurrence of HCC after the initial operation. Different MVI patterns affect survival after the second hepatectomy. Because MVI represents the biological behavior of HCC, we place a high premium on the clinical value of MVI after each hepatectomy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatectomy; Hepatocellular carcinoma; Microvascular invasion; Recurrence

Mesh:

Year:  2015        PMID: 26259778     DOI: 10.1016/j.jss.2015.06.069

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study.

Authors:  Xiu-Ping Zhang; Kang Wang; Xu-Biao Wei; Le-Qun Li; Hui-Chuan Sun; Tian-Fu Wen; Zong-Tao Chai; Zhen-Hua Chen; Jie Shi; Wei-Xing Guo; Dong Xie; Wen-Ming Cong; Meng-Chao Wu; Wan Yee Lau; Shu-Qun Cheng
Journal:  Oncologist       Date:  2019-05-28

2.  The impact of tumor burden at the initial hepatectomy on the recurrence-to-death survival after repeat surgical resection/radiofrequency ablation: a retrospective study.

Authors:  Youwei Wu; Wei Peng; Junyi Shen; Xiaoyun Zhang; Chuan Li; Tianfu Wen
Journal:  BMC Surg       Date:  2022-05-18       Impact factor: 2.030

3.  A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma.

Authors:  Jeroen Dekervel; Dusan Popovic; Hannah van Malenstein; Petra Windmolders; Line Heylen; Louis Libbrecht; Ashenafi Bulle; Bart De Moor; Eric Van Cutsem; Frederik Nevens; Chris Verslype; Jos van Pelt
Journal:  Transl Oncol       Date:  2016-04       Impact factor: 4.243

4.  VEGF Overexpression Predicts Poor Survival in Hepatocellular Carcinoma.

Authors:  Sae Byeol Choi; Hyung Joon Han; Wan Bae Kim; Tae Jin Song; Sang Yong Choi
Journal:  Open Med (Wars)       Date:  2017-12-09

5.  Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a single-center study.

Authors:  Pusen Wang; Hao Li; Baojie Shi; Weitao Que; Chunguang Wang; Junwei Fan; Zhihai Peng; Lin Zhong
Journal:  Oncotarget       Date:  2016-06-07

6.  Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria.

Authors:  Yi-Fu Hou; Bo Li; Yong-Gang Wei; Jia-Yin Yang; Tian-Fu Wen; Ming-Qing Xu; L V-Nan Yan; Ke-Fei Chen
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.